What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Risankizumab has demonstrated clear clinical advantages over placebo in three randomized controlled trials, with statistically significant improvements in primary and secondary endpoints, including ACR and PASI response rates. However, it has not been directly compared to other biological DMARDs, which limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The cost comparison analysis indicates that risankizumab is likely to be cost-effective, with total costs similar to or lower than those of guselkumab, which is a key comparator. The analysis aligns with NICE’s cost-effectiveness thresholds.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests moderate improvements in HRQoL metrics, particularly through the PASI scores, indicating positive impacts on skin symptoms. However, specific HRQoL data from validated instruments were not detailed in the document.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Risankizumab has shown a very good safety profile, with no significant differences in adverse events compared to guselkumab. The evidence suggests that adverse events are mostly mild to moderate, supporting its tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The document indicates that risankizumab was compared to guselkumab, which is appropriate given the similar mechanisms of action and the context of treatment for active psoriatic arthritis. However, the lack of direct comparisons with other biological DMARDs is a limitation.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a diverse population of adults with active psoriatic arthritis, and the results are considered generalizable to the intended patient population. However, there are some limitations regarding the subgroup with prior biological DMARD use.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Risankizumab can be integrated into existing treatment pathways with minor adjustments, as it aligns with current clinical practices for assessing treatment response at 16 weeks.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact analysis indicates that the resource implications of adopting risankizumab are manageable, with costs being similar to those of existing treatments. This suggests a justifiable cost burden relative to the benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on multiple randomized controlled trials with a total of 1,592 participants, providing a robust foundation. However, some methodological concerns and the reliance on indirect comparisons introduce some uncertainty.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the indirect comparisons and subgroup analyses, the overall context of unmet need and the alignment with clinical practice help mitigate these concerns.
